Eledon Pharmaceuticals (ELDN) Cash & Current Investments (2013 - 2026)

Eledon Pharmaceuticals has reported Cash & Current Investments for 14 years, with the latest figure at $216.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 72.99% year-over-year to $216.0 million; the trailing twelve-month figure through Mar 2026 stood at $216.0 million (up 72.99% YoY), and the FY2025 full-year result was $133.3 million, down 4.88% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $216.0 million, up from $133.3 million in the prior quarter.
• The five-year high for Cash & Current Investments was $216.0 million in Q1 2026, with the low at $9.2 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $92.7 million across 5 years, with a median of $83.6 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments sank 90.22% — and 2023, when it soared 1155.89%.
• Eledon Pharmaceuticals' Cash & Current Investments stood at $56.4 million in 2022, then decreased by 9.41% to $51.1 million in 2023, then surged by 174.31% to $140.2 million in 2024, then fell by 4.88% to $133.3 million in 2025, then soared by 62.02% to $216.0 million in 2026.
• The last three Cash & Current Investments figures came in at $216.0 million (Q1 2026), $133.3 million (Q4 2025), and $183.1 million (Q3 2025), per Business Quant data.